

16 January 2017

Expiry of ANPO Listing Options

The Company wishes to advise that the Australian Securities Exchange (ASX) has granted Antisense Therapeutics Limited (ANP), 'the Company', a waiver from ASX Listing Rule 6.24 to the extent necessary to permit the Company not to send expiry notices to optionholders as usually required by item 6.1 of Appendix 6A in relation to the expiration of the ANPO listed options exercisable at \$0.27 per option on or before 31 January 2017.

Pursuant to item 6.1 of Appendix 6A the Company is required to disclose the following information with respect to the expiring ANPO listed options:

| | |
|---|--|
| Number of Securities to Expire | 46,950,984 |
| Class of Expiring Securities | Listed Options |
| ASX Code | ANPO |
| Exercise Price per Security | \$0.27 |
| Expiry Date | 31 January 2017 |
| Due Date for Payment | 31 January 2017 |
| Result of non-exercise of securities by due date | Unexercised options will be forfeited and lapse |
| Securities Quotation Ending Date | Wednesday 25 th January 2017 |
| Underlying Share Price as at 13 th Jan 2017 | \$0.044 per share |
| Highest and Lowest Market Price of Share during the last 3 months | Low: \$0.033 (10 th November 2016) High: \$0.053 (10 th January 2017) |

Contact Information: Website: www.antisense.com.au
 Managing Director: Mark Diamond +61 (0)3 9827 8999

Antisense Therapeutics Limited (ASX: ANP) is an Australian publicly listed biopharmaceutical drug discovery and development company. Its mission is to create, develop and commercialise second generation antisense pharmaceuticals for large unmet markets. ANP has 4 products in its development pipeline that it has in-licensed from Isis Pharmaceuticals Inc., world leaders in antisense drug development and commercialisation - ATL1102 (injection) which has successfully completed a Phase II efficacy and safety trial, significantly reducing the number of brain lesions in patients with relapsing-remitting multiple sclerosis (RRMS), ATL1103 drug designed to block GHR production which in a Phase II clinical trial, successfully reduced blood IGF-I levels in patients with the growth disorder acromegaly, ATL1102 (inhaled) which is at the pre-clinical research stage as a potential treatment for asthma and ATL1101 a second-generation antisense drug at the pre-clinical stage being investigated as a potential treatment for cancer.